These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22261728)

  • 1. A rare 'palisading' enhancing pattern of multiple sclerosis.
    Huang CF; Lo CP; Tseng CY; Chen YC
    Eur Neurol; 2012; 67(3):161. PubMed ID: 22261728
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving combination trials for multiple sclerosis.
    Trojano M
    Lancet Neurol; 2010 Jul; 9(7):646-7. PubMed ID: 20542737
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical practice. Optic neuritis.
    Balcer LJ
    N Engl J Med; 2006 Mar; 354(12):1273-80. PubMed ID: 16554529
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.
    Dastgir J; DiMario FJ
    J Child Neurol; 2009 Apr; 24(4):431-7. PubMed ID: 19189932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
    Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
    Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Magnetic resonance angiography in multiple sclerosis].
    Pati DV; Vorobeĭchik G
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):53-7. PubMed ID: 10629934
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 13. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment with beta-interferon should be started already after the first attack of MS].
    Söderström M
    Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
    Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
    Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
    Barkhof F; van Waesberghe JH; Uitdehaag BM; Polman CH
    Ann Neurol; 1997 Dec; 42(6):982. PubMed ID: 9403493
    [No Abstract]   [Full Text] [Related]  

  • 17. Axonal damage in multiple sclerosis: a complex issue in a complex disease.
    Grigoriadis N; Ben-Hur T; Karussis D; Milonas I
    Clin Neurol Neurosurg; 2004 Jun; 106(3):211-7. PubMed ID: 15177770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
    Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
    Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.